Vicore Pharma HOME ABOUT US TECHNOLOGY RESEARCH NEWS CONTACT US INVESTOR Aktien Company Presentations Vicore Pharma is A drug-development company at the international cutting edge of research on the AT2 receptor. The company's portfolio contains small molecules with potential indications including anti-inflammation, nerve generation and cardiovascular disease. Our vision is to lead the development of new molecules with agonistic action to the AT2 receptor into successful clinical drug entities. News C21 may protect the heart from chemotherapy toxicity 2016-09-27 C21 kan ge hjärtskydd vid cytostatikabehandling 2016-09-27 Show more news The AT2 receptor The AT2 receptor is expressed and activated in the fetus where it supports organ development and differention, and in damaged adult tissue where it restitutes morphology and function, restores heart function after myocardial infarction, reduces inflammation, regenerates neural tissue - to mention but a few of the beneficial effects. Calender Bio Japan 2016-10-12 - 2016-10-14Pacifico, Yokohama, Japan Delårsrapport Jan-Okt, 2016 2016-10-13 Show more events c/o Astra Zeneca, Pepparedsleden 1, SE-431 83 Mölndal, Phone +46 (0)31 78 80 560